Staff
Janice Reichert, PhD, Executive Director
Dr. Janice Reichert, Executive Director of The Antibody Society, is an internationally-recognized expert in the development of antibody therapeutics. She is Founder and Managing Director of Reichert Biotechnology Consulting LLC, a biopharmaceutical business intelligence research firm, and Founder and Editor-in-Chief of mAbs, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development. Dr. Reichert has published extensively on development trends for antibody therapeutics, and she has presented her research results as an invited speaker at conferences held worldwide. Dr. Reichert received her PhD in Chemistry from the University of Pennsylvania and did her post-doctoral training at Harvard Medical School.
Relevant links:
Editor-in-chief, mAbs
Kaplon H, Chenoweth A, Crescioli S, Reichert JM, Antibodies to watch in 2022. mAbs 2022
Volunteers
Communications & Membership Committee
Raquel Barroso Ferro, University of Aberdeen.
Raquel Barroso Ferro, student volunteer for the Education and Career Sub-Committee, is a first year PhD student at the University of Aberdeen, UK, currently working to develop a novel scFv-based immunotherapy against ovarian cancer. She previously completed an integrated Master’s in Biochemistry (MSci) from King’s College London and worked as a research assistant evaluating how various environmental chemicals can influence aspects of the human physiology. @ LinkedIn
Silvia Crescioli, PhD, King’s College London
Dr. Silvia Crescioli is a senior post doc at King’s College London in Prof. Sophia Karagiannis’ Cancer Antibody Discovery & Immunotherapy Group, where she leads and supervises several projects focused on different areas of cancer immunology and immunotherapy, such as the study of B cells in cancer, antigen/antibody discovery, ADC development, and antibody production, engineering and glycoengineering. Dr. Crescioli received her PhD in Biomedical Sciences, Experimental Oncology, from the University of Florence. @ King’s College London;
Scientific publications
Nick Hutchinson, PhD, FUJIFILM
Dr. Nick Hutchinson is the Business Steering Group Lead for Mammalian Cell Culture processes at FUJIFILM Diosynth Biotechnologies, a contract development and manufacturing service provider for biopharmaceutical clients. He is part of the Enterprise Business Planning team and focuses on long-term projects, including capital investments and innovation. His expertise is in the biomanufacturing of biopharmaceuticals, in particular antibody therapeutics from cell line development activities through to commercial production. Dr. Hutchinson is currently an Assistant Editor for mAbs and received his Doctorate in Biochemical Engineering from University College London.
Recent presentations and publications:
Hutchinson N. 2020. Antibody Manufacturing Strategies to Address a Pandemic. Festival of Biologics. November 02-06, 2020
Reichert JM & Hutchinson N. 2020. Antibodies to Watch in 2021: Anti-SARS-CoV-2 target therapies to the rescue. The Antibody Society Webinar Series “Antibodies to Watch”. December 3, 2020. Watch it online
Hutchinson N. 2020. Tracking Therapeutic Antibody Development in a Pandemic. BioProcess International. October 2020.
Alicia Chenoweth, PhD, King’s College London
Dr. Alicia Chenoweth is a postdoctoral research associate in the Cancer Antibody Discovery and Immunotherapy group led by Prof. Sophia Karagiannis at King’s College London. Her work is focused on Fc engineering of antibodies for breast cancer therapy to better engage and influence the immune microenvironment. She received her PhD in Melbourne, Australia, under the supervision of Prof. Mark Hogarth, focusing on the interactions of human and non-human primate IgG antibodies with Fc receptors, and the impact of IgG Fc modification on immune cell function. Dr. Chenoweth is currently the co-chair of the Gordon Research Seminar for Antibody Biology and Engineering, to be held in 2022. @ LinkedIn; Twitter
Vaishali Kapoor, PhD, Washington University in St. Louis
Dr. Vaishali Kapoor is an Assistant Professor in the Department of Radiation Oncology at the Washington University in St. Louis School of Medicine. Dr. Kapoor received her PhD in Cancer Biology from the All India Institute of Medical Sciences (New Delhi, India) and did her postdoctoral training at the Washington University School of Medicine. Her research involves development of novel drug candidates against radiation-inducible neo-antigens. Her lab is developing ways to target radiation sensitizers specifically to cancer with the goal of enhancing the efficacy of radiation therapy. Dr. Kapoor is also interested in understanding the mechanisms of resistance to standard-of-care cancer therapies. @ LinkedIn; Twitter; Washington University
Dr. Jyothsna Visweswaraiah is a scientist with drug development experience in small biotech and a track record of advancing new therapies into the clinic. She currently heads the antibody discovery and engineering efforts at a Flagship Pioneering new company called FL75, developing a modular, multi-specific biologics platform to address the complexities of biology with high resolution. Prior to FL75, Dr. Visweswaraiah was at Pandion Therapeutics where she developed novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Dr. Visweswaraiah has trained at Harvard Medical School and the National Institutes of Health. She has been an advocate for women in science and workplace inclusiveness. She mentors students interested in STEM careers, early career women scientists and serves on the Advisory Board of WEST, a non-profit organization supporting early to mid-career women. In recognition of her accomplishments, Dr. Visweswaraiah was nominated for the 2021 James S. Huston Antibody Science Talent Award.
